ライフサイエンスコーパス: angiotensin receptor blocker

1 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.

2 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.

3 c agent that combines a NEP inhibitor and an angiotensin receptor blocker.

4 n either stand-alone neprilysin inhibitor or angiotensin receptor blocker.

5 and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.

6 f angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.

7 ngiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker.

8 angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers.

9 of the next generation of beta-blockers and angiotensin receptor blockers.

10 angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

11 angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

12 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

13 angiotensin converting-enzyme inhibitors and angiotensin receptor blockers.

14 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

15 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

16 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

17 zyme, and synthesis of its inhibitors and of angiotensin receptor blockers.

18 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

19 angiotensin-converting-enzyme inhibitors, or angiotensin-receptor blockers.

20 is of unproven value, even beta-blockers and angiotensin-receptor blockers.

21 angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.

22 (ACE) inhibitors (1.08, 1.02-1.15, p=0.008), angiotensin-receptor blockers (1.16, 1.07-1.25, p=0.0002

23 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (18.2% vs 16.9%, p = 1.000

24 for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (66% versus 68%; P=0.04) a

25 iotensin-converting enzyme inhibitors and/or angiotensin receptor blockers achieves only partial reno

26 An angiotensin receptor blocker added to an ACE inhibitor m

27 angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers after SAVR for severe AS b

28 angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers after surgical aortic valv

29 When given with an angiotensin receptor blocker, aliskiren produces signifi

30 re angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, alpha-blockers, beta-bloc

31 ngiotensin-converting enzyme inhibitor or an angiotensin receptor blocker and appropriate limitation

32 : high dose, 0.55; low dose, 0.72; both ACEi/angiotensin receptor blocker and beta-blocker: high dose

33 ate, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and oral anti-diabetic agen

34 Telmisartan, an angiotensin receptor blocker and partial PPAR-gamma agon

35 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and 82% were receiving bet

36 expression is ameliorated by antiproteinuric angiotensin receptor blockers and angiotensin-converting

37 ith angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-blockers and an o

38 use angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-blockers compared

39 Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers were pre

40 edications include calcium channel blockers, angiotensin receptor blockers and converting enzyme inhi

41 For patients with persistent symptoms, angiotensin-receptor blockers and aldosterone antagonist

42 (angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers and statins), and adverse

43 (angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers and statins), and adverse

44 angiotensin converting enzyme inhibitor, and angiotensin receptor blocker), and N-terminal probrain n

45 osemide, diltiazem, aspirin, simvastatin, an angiotensin receptor blocker, and insulin.

46 We evaluated the ability of irbesartan, an angiotensin receptor blocker, and lipoic acid, an antiox

47 ing angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and 4.5 million not recei

48 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and aldosterone antagonis

49 aneurysmal disease, including beta-blockers, angiotensin receptor blockers, and angiotensin-convertin

50 ns, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and beta-blockers, respec

51 th angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium antagonists y

52 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and dietary protein restr

53 s, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers, and diuretics.

54 of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and more sunscreen use in

55 s, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and other agents affect c

56 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and P2Y12 antagonists) re

57 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins (combination

58 rs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins after acute m

59 rs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins reduces cardi

60 n, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and beta-adrenergic block

61 irm the beneficial effect of ACE-inhibitors, angiotensin-receptor blockers, and diuretics and/or beta

62 tency is approximately equivalent to that of angiotensin receptor blockers, angiotensin-converting en

63 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, antiplatelet drugs, beta-

64 Angiotensin receptor blockers appear to be as effective

65 1.73 m(-2)), greater renal vasodilation with angiotensin receptor blockers (approximately 145 mL x mi

66 ]: 1.04 to 1.10) and discharge ACE inhibitor/angiotensin receptor blocker (ARB) in LV dysfunction (64

67 tensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) on atherosclerotic ev

68 The combination of a diuretic and an angiotensin receptor blocker (ARB) or angiotensin-conver

69 ensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) should be used for se

70 nical trials (RCT), ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy have emerged

71 ed in increased cancer risk, with a focus on angiotensin receptor blocker (ARB) therapy, as recent pu

72 1) but had similar rates of ACE inhibitor or angiotensin receptor blocker (ARB) use (85.7% black vs 8

73 giotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) use and mortality in

74 otensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) use, ESA use, dialysi

75 ensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are generally well t

76 nsin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) doses on outcomes in

77 The advent of orally active angiotensin receptor blockers (ARB) increases the number

78 ensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) initiated after myoc

79 otensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), beta-blockers (BB),

80 At last follow-up, with the use of angiotensin receptor blockers (ARB), the Up/c declined t

81 ensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).

82 tly less likely after dual treatment with an angiotensin-receptor blocker (ARB) and an angiotensin-co

83 To determine whether the angiotensin-receptor blocker (ARB) candesartan decreases

84 otensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) for patients with lef

85 iotensin-converting enzyme inhibition and/or angiotensin-receptor blocker (ARB) therapy (group 1) wer

86 nsin-converting-enzyme (ACE) inhibitors with angiotensin-receptor blockers (ARB).

87 irectly inhibit the angiotensin II receptor (angiotensin receptor blocker [ARB]) has provided clinici

88 nin angiotensin system pathways suggest that angiotensin receptor blockers (ARBs) are ideal drugs to

89 nsin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are widely prescrib

90 nsin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are widely prescrib

91 The use of angiotensin receptor blockers (ARBs) correlates with red

92 ertensive patients (n = 469), patients using angiotensin receptor blockers (ARBs) did not show a decl

93 PURPOSE OF REVIEW: As their introduction, angiotensin receptor blockers (ARBs) have been widely pr

94 ensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) improves left ventr

95 tensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in patients with ty

96 ensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in preventing the n

97 several years have examined indications for angiotensin receptor blockers (ARBs) in the treatment of

98 Because angiotensin receptor blockers (ARBs) lack a direct effec

99 Preclinical data suggest that angiotensin receptor blockers (ARBs) may have similar st

100 sin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) may increase the ri

101 in-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) on the composite of

102 iotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin (

103 iotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, and

104 otensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), beta-blockers, and

105 target the renin angiotensin system, such as angiotensin receptor blockers (ARBs), have been associat

106 lyses assessed therapeutic substitution with angiotensin receptor blockers (ARBs).

107 tensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).

108 Angiotensin-receptor blockers (ARBs) are a widely used d

109 Angiotensin-receptor blockers (ARBs) are effective treat

110 ensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinur

111 The role of angiotensin-receptor blockers (ARBs) in treating patient

112 ensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) reduce cardiovascul

113 tensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) who filled brand-na

114 ensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs), 3-hydroxy-3-methyl

115 allergic myocardial infarction, anaphylaxis, angiotensin-receptor blockers (ARBs), beta-adrenergic bl

116 recent analysis showing increased risk with angiotensin-receptor blockers (ARBs).

117 tensin-converting enzyme inhibitors [ACEIs], angiotensin receptor blockers [ARBs], and beta-blockers

118 nsin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs], and cilostazol) an

119 used in the clinic AT(1)R antagonist drugs (angiotensin receptor blockers, ARBs, or sartans) at prev

120 Angiotensin receptor blockers are renoprotective in hype

121 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker at discharge, have little r

122 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers at admission), beta-blocke

123 of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers at discharge decreased in

124 g angiotensin converting enzyme inhibitor or angiotensin receptor blocker background therapy.

125 sing angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (beta=0.36, P<0.001; CI: 0.

126 tensin-converting enzyme inhibitor (ACEi, or angiotensin receptor blocker), beta-blocker, or both dru

127 n patients receiving higher doses of ACEi or angiotensin receptor blocker, beta-blocker, or both (haz

128 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta blockers, calcium ch

129 of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, aldosteron

130 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, aldosteron

131 Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and aldost

132 ns, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, and dual a

133 ns, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, and dual a

134 sed angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, and statin

135 (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, spironolac

136 ing angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, beta-blockers, and devic

137 of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, beta blockers, calcium-ch

138 ng angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, beta-blockers, and minera

139 s (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, beta-blockers, calcium ch

140 an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, calcium channel blocker, o

141 ., angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, calcium channel blockers,

142 ) administration of ultrahigh dosages of the angiotensin receptor blocker candesartan on the progress

143 clinical trial, comparing the effects of the angiotensin receptor blocker candesartan with placebo in

144 The angiotensin receptor blocker component of LCZ696, valsar

145 We aimed to find out whether the use of an angiotensin-receptor blocker could reduce mortality and

146 We aimed to find out whether candesartan, an angiotensin-receptor blocker, could improve outcome in s

147 f angiotensin-convering enzyme inhibitors or angiotensin receptor blockers during the study and a his

148 cardiovascular examples, such as the use of angiotensin receptor blockers for chronic heart failure,

149 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for secondary prevention a

150 (3) angiotensin-converting enzyme inhibitor/angiotensin receptor blockers for systolic dysfunction,

151 he therapeutic benefits of beta-blockers and angiotensin receptor blockers given the emerging concept

152 ted, whereas acute HF and patients receiving angiotensin receptor blocker had higher plasma Ang II wi

153 been demonstrated that Valsartan (Val) as an angiotensin receptor blocker has renoprotective effects,

154 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers has become a crucial eleme

155 Specific benefits beyond those of other angiotensin receptor blockers have been claimed for tele

156 nd clinical data support the hypothesis that angiotensin receptor blockers have beneficial effects on

157 angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have demonstrated benefici

158 Angiotensin receptor blockers have not been shown to be

159 vitro, specific actions not shared by other angiotensin receptor blockers have not yet been convinci

160 rd ratio for eplerenone versus placebo, ACEi/angiotensin receptor blocker: high dose, 0.67; low dose,

161 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (HR, 0.90; 95% CI, 0.79-1.

162 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ie, renin-angiotensin sys

163 Thiazide diuretics, ACE-inhibitors or angiotensin receptor blockers if ACE-inhibitor-intoleran

164 uggest that aliskiren was as effective as an angiotensin receptor blocker in attenuating this measure

165 r angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in eligible patients.

166 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in persons with CKD to impr

167 rdial infarction patients suggest a role for angiotensin receptor blockers in patients with heart fai

168 ngiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with heart fai

169 Available data support the use of angiotensin receptor blockers in persons with type 2 dia

170 w data exist concerning the effectiveness of angiotensin receptor blockers in this population.

171 definitive studies have examined the use of angiotensin-receptor blockers in patients with type 2 di

172 in-converting enzyme inhibitor) or losartan (angiotensin-receptor blocker) in FSGS mice stimulated th

173 ngiotensin-converting enzyme inhibitors, and angiotensin receptor blockers increased by 23%, 57%, 31%

174 ensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers increases the likelihood o

175 Treatment for 4 weeks with the angiotensin receptor blocker irbesartan, but not with th

176 transinhibitory effect of beta-blockers and angiotensin receptor blockers is through receptor-G prot

177 The angiotensin receptor blocker losartan was given to half

178 st orally active direct renin inhibitor, the angiotensin-receptor blocker losartan, and their combina

179 itors (captopril, fosinopril, ramipril), and angiotensin receptor blockers (losartan, candesartan).

180 w warranted to establish the extent to which angiotensin receptor blockers may provide antiinflammato

181 ean BP reduction 12.9/7.7 mm Hg; p < 0.003), angiotensin-receptor blockers (mean BP reduction 13.3/7.

182 for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartil

183 Combined angiotensin receptor blocker neprilysin inhibitors (ARNI

184 ng the effects of aliskiren combined with an angiotensin receptor blocker on intermediate markers of

185 etermine the effects of pretreatment with an angiotensin receptor blocker on left ventricular (LV) fu

186 f the study was to evaluate the effect of an angiotensin receptor blocker on left ventricular (LV) st

187 giotensin receptor neprilysin inhibitor with angiotensin receptor blocker on Management Of heart fail

188 unity to examine the long-term effects of an angiotensin receptor blocker on plasma aldosterone level

189 and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on outcome in patients wit

190 ting the renoprotective benefit of adding an angiotensin receptor blocker or a mineralocorticoid rece

191 e of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or beta-blocker and 60- to

192 DMT (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, or beta-blocker) at baseli

193 le angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or both.

194 of angiotensin converting enzyme inhibitors/angiotensin receptor blockers (P = 0.02).

195 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (p = 0.029), higher biliru

196 ile lower ATP was associated with the use of angiotensin receptor blockers (P=0.015).

197 ACE-inhibitors and angiotensin-receptor blockers remain excellent first lin

198 (+) intake and angiotensin converting enzyme/angiotensin receptors blockers Rx.

199 Angiotensin receptor blockers should be reserved for mon

200 Although angiotensin receptor blockers should not be considered e

201 ngiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, should generally be includ

202 -blockers, angiotensin-converting inhibitors/angiotensin receptor blockers, statins, diabetic treatme

203 erting-enzyme inhibitor (lisinopril) plus an angiotensin-receptor blocker (telmisartan) or lisinopril

204 eive angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy (P<0.01).

205 from the combination of an ACE-inhibitor and angiotensin receptor blocker therapy in patients with va

206 giotensin-converting enzyme inhibitor and/or angiotensin receptor blocker therapy is the standard of

207 angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy on patients who hav

208 d angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, 100% beta-blocker

209 d angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, 35% beta-blocker t

210 d angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, 51% beta-blocker t

211 for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confide

212 Angiotensin-converting enzyme inhibition/angiotensin-receptor blocker therapy is well tolerated i

213 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker throughout the study.

214 Angiotensin receptor blocker treatment may blunt the har

215 nd to identify patients who can benefit from angiotensin receptor blocker treatment.

216 of associations and to explore the impact of angiotensin receptor blocker treatment.

217 Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker uptake increased from 46% t

218 r angiotensin-converting enzyme inhibitor or angiotensin receptor blocker usage during continuous flo

219 d angiotensin converting enzyme inhibitor or angiotensin receptor blocker usage were not significantl

220 y angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use at discharge was associ

221 .5%, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use in 24.9+/-1.9%, and asp

222 and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use in patients with an Ame

223 s in angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use or anticoagulation for

224 , angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, and nonsmoking status-

225 Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, beta-blocker use, anti

226 and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use-is well suited to provi

227 were randomly assigned to receive either the angiotensin receptor blocker valsartan (titrated to 320

228 rketed by Novartis as Entresto) combines the angiotensin receptor blocker valsartan and the neprilysi

229 Furthermore, administration of the angiotensin receptor blocker valsartan to intact mice re

230 the long-term effects of the addition of the angiotensin-receptor blocker valsartan to standard thera

231 e-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibito

232 An angiotensin receptor blocker was administered at time 18

233 Chronic treatment with angiotensin receptor blockers was associated with better

234 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was indicated in 18.1% of

235 channel blockers (CCBs), alpha-blockers, and angiotensin receptor blockers-was significantly better t

236 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, which together explained

237 etic subjects not treated with ACE inhibitor/angiotensin receptor blocker who had the TT-ID-AA/AC gen

238 converting enzyme inhibitors or losartan, an angiotensin receptor blocker, will decrease the rate of

239 loped by scientists at Novartis, combines an angiotensin receptor blocker with a neprilysin inhibitor

240 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with well controlled BP an